Form 8-K

8-K — Telomir Pharmaceuticals, Inc.

Accession: 0001493152-26-028614

Filed: 2026-06-15

Period: 2026-06-15

CIK: 0001971532

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001971532

2026-06-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): June 15, 2026

TELOMIR

PHARMACEUTICALS, INC.

(Exact

Name of Registrant as Specified in its Charter)

Florida

001-41952

87-2606031

(State

or Other Jurisdiction

(Commission

(IRS

Employer

of Incorporation)

File Number)

Identification No.)

100

SE 2nd St, Suite 2000, #1009

Miami,

Florida 33131

(Address

of Principal Executive Offices)

Registrant’s

telephone number, including area code: (786) 396-6723

Not

Applicable

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of each

class

Trading Symbol

Name of each exchange on

which registered

Common

Stock, no par value

TELO

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

June 15, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the peer-reviewed publication

of preclinical data relating to Telomir-Zn in Biomedicine & Pharmacotherapy, in a manuscript entitled “Telomir-Zn Restores

Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes.”

The

publication reports that Telomir-Zn produced dose-dependent improvements in fasting blood glucose, glucose tolerance, fasting insulin

levels, and insulin resistance, as measured by HOMA-IR, in a diet-induced zebrafish model of Type 2 diabetes mellitus. The findings provide

additional peer-reviewed evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis

and further expand the scientific foundation underlying the Company’s lead clinical program.

The

publication is the Company’s second peer-reviewed publication in 2026, supporting the biological mechanism of Telomir-Zn. Telomir-Zn

has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for the Company’s Phase 1/2 clinical

trial (TELO-001) in patients with advanced or metastatic triple-negative breast cancer.

copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The

information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into

any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Other Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release of Telomir Pharmaceuticals, Inc., dated June 15, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

TELOMIR PHARMACEUTICALS, INC.

Dated: June 15, 2026

By:

/s/ Erez

Aminov

Name:

Erez Aminov

Title:

Chief Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

Telomir

Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity

with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Insulin

Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further

Validating Telomir-Zn’s Metal-Homeostasis Mechanism Across Multiple Disease Models.

MIAMI,

FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (“Telomir” or the “Company”),

a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and

age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity

and significant improvement in glucose homeostasis with Telomir-Zn in a diet-induced zebrafish model of Type 2 diabetes mellitus (T2DM).

The

manuscript, titled “Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model

of Type 2 Diabetes,” has been published in Biomedicine & Pharmacotherapy.

The

publication is available online in Biomedicine & Pharmacotherapy.

Publication

Highlights

Type

2 diabetes mellitus is characterized by chronic hyperglycemia, impaired glucose utilization, and insulin resistance. Insulin resistance

is a central driver of disease progression and is associated with oxidative stress, mitochondrial dysfunction, and metabolic dysregulation.

the study, zebrafish fed a high-calorie diet developed significant metabolic dysfunction, including fasting hyperglycemia, hyperinsulinemia,

impaired glucose tolerance, and HOMA-IR values of approximately 10–12, consistent with severe insulin resistance.

According

to the publication, treatment with Telomir-Zn produced dose-dependent improvements across multiple independent measures of metabolic

health, including:

● Significant

reduction in fasting blood glucose levels to near control levels

●

Improved glucose clearance during oral glucose tolerance testing (OGTT)

●

Reduction in fasting insulin concentrations

●

Significant improvement in HOMA-IR, a widely used measure of insulin resistance

Most

notably, HOMA-IR values declined from approximately 10–12 in untreated diabetic animals to approximately 3 following 14 days of

treatment, representing a substantial reversal of insulin resistance. Improvements were observed in a dose-dependent manner and remained

consistent across both Day 7 and Day 14 assessments.

The

authors concluded that Telomir-Zn restored key metabolic parameters associated with insulin resistance and glucose dysregulation, supporting

further investigation of metal-modulating small molecules as a novel therapeutic approach for metabolic disease.

Mechanistic

Relevance to Telomir-Zn’s Clinical Development Program

The

publication adds to a growing body of peer-reviewed evidence supporting Telomir-Zn’s mechanism of action through modulation of

intracellular metal homeostasis.

Accumulating

scientific evidence suggests that dysregulation of intracellular iron and zinc balance contributes to oxidative stress, mitochondrial

dysfunction, and altered cellular signaling across multiple disease states. In metabolic disease, these processes can impair insulin

receptor signaling and glucose homeostasis. In cancer, similar pathways have been implicated in epigenetic dysregulation, treatment resistance,

tumor progression, and aggressive disease biology.

Telomir-Zn

was designed to modulate intracellular metal homeostasis and influence iron-dependent biological pathways through a zinc-coordinated

small-molecule platform.

While

Type 2 diabetes and triple-negative breast cancer represent distinct disease states, both involve oxidative stress, dysregulated metal

homeostasis, and iron-dependent cellular signaling pathways targeted by Telomir-Zn.

The

Company believes these findings provide additional independent, peer-reviewed validation of biological pathways underlying its lead clinical

program. Telomir-Zn recently received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the

Company’s Phase 1/2 clinical trial (TELO-001) in patients with advanced or metastatic triple-negative breast cancer.

Management

Commentary

“What

makes these findings particularly interesting is that excess intracellular iron has been implicated in both insulin resistance and cancer

biology,” said Dr. Itzchak Angel, Chief Scientific Advisor of Telomir Pharmaceuticals and corresponding author of the publication.

“In

diabetes, iron-driven oxidative stress can impair insulin signaling and glucose metabolism. In cancer, iron-dependent pathways can contribute

to epigenetic dysregulation and tumor progression. The ability of Telomir-Zn to produce meaningful biological effects in multiple disease

models further strengthens our confidence that modulation of intracellular metal homeostasis may represent an important therapeutic strategy.”

“This

publication represents our second peer-reviewed publication on Telomir-Zn in 2026, supporting the biological mechanism underlying Telomir-Zn,”

said Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals.

“Combined

with our recently published Wilson’s disease findings and our FDA-cleared Phase 1/2 TNBC program, we continue to build a growing

body of scientific evidence supporting the broader potential of our metal-homeostasis platform. We now have an FDA-cleared IND, preparations

underway for our Phase 1/2 TNBC study, and multiple peer-reviewed publications supporting our underlying biology. Our focus remains on

execution as we advance Telomir-Zn into human clinical trials.”

About

Telomir Pharmaceuticals

Telomir

Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic

and metabolic pathways implicated in cancer, aging, and degenerative disease. The Company’s lead program, Telomir-Zn, is designed

to modulate intracellular metal homeostasis and epigenetic regulation and has received IND clearance from the U.S. Food and Drug Administration

for a Phase 1/2 clinical trial in Triple-Negative Breast Cancer. For more information, please visit https://telomirpharma.com/.

Forward-Looking

Statements

This

press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of

1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,”

“plan,” “can,” “could,” “would,” “may,” “will,” “believe,”

“estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,”

“intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements

include these words.

Forward-looking

statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans,

regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s

other product candidates. Forward-looking statements may also include statements regarding the significance of the published preclinical

findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s

Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

These

forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs

and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those

expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical

development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property

protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained

in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission

(“SEC”).

Forward-looking

statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise

such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to

read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion

of these and other risks and uncertainties.

Contact Information

Krystina

Quintana

Email: info@telomirpharma.com

Phone: (786) 396-6723

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 15, 2026

Entity File Number

001-41952

Entity Registrant Name

TELOMIR

PHARMACEUTICALS, INC.

Entity Central Index Key

0001971532

Entity Tax Identification Number

87-2606031

Entity Incorporation, State or Country Code

Entity Address, Address Line One

100

SE 2nd St

Entity Address, Address Line Two

Suite 2000

Entity Address, Address Line Three

#1009

Entity Address, City or Town

Miami

Entity Address, State or Province

Entity Address, Postal Zip Code

33131

City Area Code

(786)

Local Phone Number

396-6723

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, no par value

Trading Symbol

TELO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration